Folitixorin - ADVENTRX

Drug Profile

Folitixorin - ADVENTRX

Alternative Names: 5-10 Methylenetetrahydrofolate; 5-FU biomodulator - ADVENTRX; ANX-510; CoFactor; Methylenetetrahydrofolic acid

Latest Information Update: 30 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sahlgrenska University Hospital; University of Southern California
  • Developer ADVENTRX Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Argentina (IV)
  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Mexico (IV)
  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Peru (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top